Advertisement

Clinical Presentation and Diagnosis

  • Arezou Abbasi
  • Amir A. Rahnemai-Azar
  • Sean M. Ronnekleiv-Kelly
  • Daniel E. Abbott
  • Sharon M. WeberEmail author
Chapter

Abstract

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor after hepatocellular carcinoma. In recent years, there has been an increasing trend in the incidence and mortality rate of ICC worldwide. In general, the outcome of patients with ICC is dismal, mainly due to late diagnosis and lack of effective treatment options. Detection of the tumor at early stages may make surgical resection, as the only potentially curative treatment, more feasible. Identifying ICC-specific diagnostic and prognostic biomarkers has been a focus of interest among many investigators. Unfortunately, despite recent developments in imaging modalities and laboratory tests, the diagnosis of ICC remains challenging and the majority of patients are not amenable to surgical resection at the time of presentation. Herein, we provide an overview of the current modalities used in the diagnosis of ICC.

Keywords

Biliary tract cancer Liver tumor Intrahepatic cholangiocarcinoma Diagnosis Biomarker Imaging 

References

  1. 1.
    Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–79.CrossRefGoogle Scholar
  2. 2.
    Hill MA, Alexander WB, Guo B, Kato Y, Patra KC, O’Dell MR, et al. Kras and Tp53 mutations cause cholangiocyte-and hepatocyte-derived cholangiocarcinoma. Cancer Res. 2018;78(16):4445–51.CrossRefGoogle Scholar
  3. 3.
    Andersen JB. Molecular pathogenesis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2015;22(2):101–13.CrossRefGoogle Scholar
  4. 4.
    Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010;2(12):419.CrossRefGoogle Scholar
  5. 5.
    Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261.CrossRefGoogle Scholar
  6. 6.
    Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512.CrossRefGoogle Scholar
  7. 7.
    Nathan H, Aloia TA, Vauthey J-N, Abdalla EK, Zhu AX, Schulick RD, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(1):14–22.CrossRefGoogle Scholar
  8. 8.
    Sasaki A, Aramaki M, Kawano K, Morii Y, Nakashima K, Yoshida T, et al. Intrahepatic peripheral cholangiocarcinoma: mode of spread and choice of surgical treatment. Br J Surg. 1998;85(9):1206–9.CrossRefGoogle Scholar
  9. 9.
    Olnes MJ, Erlich R. A review and update on cholangiocarcinoma. Oncology. 2004;66(3):167–79.CrossRefGoogle Scholar
  10. 10.
    Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–7.CrossRefGoogle Scholar
  11. 11.
    Khan S, Toledano M, Taylor-Robinson S. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB. 2008;10(2):77–82.CrossRefGoogle Scholar
  12. 12.
    Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis. 2010;42(7):490–5.CrossRefGoogle Scholar
  13. 13.
    von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismüller TJ, Wedemeyer H, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011;46(9):1092–8.CrossRefGoogle Scholar
  14. 14.
    Taylor-Robinson S, Toledano M, Arora S, Keegan T, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48(6):816–20.CrossRefGoogle Scholar
  15. 15.
    Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33(6):1353–7.CrossRefGoogle Scholar
  16. 16.
    Bridgewater J, Galle PR, Khan SA, Llovet JM, Park J-W, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.CrossRefGoogle Scholar
  17. 17.
    Jaiswal M, LaRusso N, Gores GJ. Cholangiocarcinoma and pro-inflammatory cytokines. Cancer Alert. 2000;1:141–4.Google Scholar
  18. 18.
    Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, et al. Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the “cholangiocarcinoma” committee of the Italian Association for the Study of liver disease. Dig Liver Dis. 2011;43(1):60–5.CrossRefGoogle Scholar
  19. 19.
    Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes1. J Am Coll Surg. 2001;193(4):384–91.CrossRefGoogle Scholar
  20. 20.
    Yedibela S, Demir R, Zhang W, Meyer T, Hohenberger W, Schönleben F. Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients. Ann Surg Oncol. 2009;16(2):404.CrossRefGoogle Scholar
  21. 21.
    Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Surgical outcomes of the mass-forming plus Periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg. 2007;31(10):2016–22.CrossRefGoogle Scholar
  22. 22.
    Bartella I, Dufour JF. Clinical diagnosis and staging of intrahepatic cholangiocarcinoma. J Gastrointestin Liver Dis (JGLD). 2015;24(4):481–9.Google Scholar
  23. 23.
    Leelawat K, Narong S, Wannaprasert J, Ratanashu-ek T. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol. 2010;16(37):4697–703.CrossRefGoogle Scholar
  24. 24.
    Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 2011;56(8):2491–6.CrossRefGoogle Scholar
  25. 25.
    Shen WF, Zhong W, Xu F, Kan T, Geng L, Xie F, et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol. 2009;15(47):5976–82.CrossRefGoogle Scholar
  26. 26.
    Liu SL, Song ZF, Hu QG, Shan D, Hu SB, Li J, et al. Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China. 2010;4(4):457–62.CrossRefGoogle Scholar
  27. 27.
    Tao LY, Cai L, He XD, Liu W, Qu Q. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg. 2010;76(11):1210–3.PubMedGoogle Scholar
  28. 28.
    Rahnemai-Azar AA, Weisbrod A, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: molecular markers for diagnosis and prognosis. Surg Oncol. 2017;26(2):125–37.CrossRefGoogle Scholar
  29. 29.
    Xu HX, Chen LD, Liu LN, Zhang YF, Guo LH, Liu C. Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol. 2012;85(1016):1029–37.CrossRefGoogle Scholar
  30. 30.
    D’Onofrio M, Crosara S, De Robertis R, Canestrini S, Mucelli RP. Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol. 2015;205(1):W56–66.CrossRefGoogle Scholar
  31. 31.
    Weber SM, Ribero D, O’reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB. 2015;17(8):669–80.CrossRefGoogle Scholar
  32. 32.
    Miller G, Schwartz LH, D’Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am. 2007;16(2):343–68.CrossRefGoogle Scholar
  33. 33.
    Vilgrain V, Van Beers BE, Flejou J-F, Belghiti J, Delos M, Gautier A-L, et al. Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J Comput Assist Tomogr. 1997;21(1):59–65.CrossRefGoogle Scholar
  34. 34.
    Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206(1):57–65.CrossRefGoogle Scholar
  35. 35.
    Lee SW, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, et al. Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinoma. J Gastroenterol. 2010;45(5):560–6.CrossRefGoogle Scholar
  36. 36.
    Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer. 2013;119(22):3929–42.CrossRefGoogle Scholar
  37. 37.
    Durot I, Wilson SR, Willmann JK. Contrast-enhanced ultrasound of malignant liver lesions. Abdom Radiol. 2018;43(4):819–47.CrossRefGoogle Scholar
  38. 38.
    Jiang W, Zeng ZC, Tang ZY, Fan J, Sun HC, Zhou J, et al. A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol. 2011;22(7):1644–52.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Arezou Abbasi
    • 1
  • Amir A. Rahnemai-Azar
    • 2
  • Sean M. Ronnekleiv-Kelly
    • 2
  • Daniel E. Abbott
    • 2
  • Sharon M. Weber
    • 2
    Email author
  1. 1.Department of SurgeryUniversity of Washington Medical CenterSeattleUSA
  2. 2.Department of Surgery, Division of Surgical OncologyUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations